Trial Watch: Adoptive cell transfer for oncological indications

One particular paradigm of anticancer immunotherapy relies on the administration of (potentially) tumor-reactive immune effector cells. Generally, these cells are obtained from autologous peripheral blood lymphocytes (PBLs) ex vivo (in the context of appropriate expansion, activation and targeting p...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Oncoimmunology
Auteurs principaux: Aranda, Fernando, Buqué, Aitziber, Bloy, Norma, Castoldi, Francesca, Eggermont, Alexander, Cremer, Isabelle, Fridman, Wolf Hervé, Fucikova, Jitka, Galon, Jérôme, Spisek, Radek, Tartour, Eric, Zitvogel, Laurence, Kroemer, Guido, Galluzzi, Lorenzo
Format: Artigo
Langue:Inglês
Publié: Taylor & Francis 2015
Sujets:
Review
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4590013/
https://ncbi.nlm.nih.gov/pubmed/26451319
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2015.1046673
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires